FDA issues letters, called current good manufacturing practice (CGMP) declarations, to foreign regulators that convey CGMP compliance status of establishments FDA has inspected.
Facilities located in the U.S. that have been included as part of a marketing application submitted to a foreign regulator request the letter from FDA. The agency then issues a letter directly to an identified foreign regulator conveying the CGMP compliance status for the facility within 30 days of receipt of the request.
A CGMP declaration should only be requested if a foreign regulator does not accept a valid certificate of pharmaceutical product (CPP) and wants additional assurance of a facility’s CGMP status.
CGMP declarations are one of several ways that FDA is enhancing communication and transparency with foreign regulatory authorities regarding the compliance status of establishments in the U.S. Foreign regulators also can find the CGMP status of an establishment by checking the FDA Data Dashboards for the most recent inspection classification.
An establishment may request a CGMP declaration using the agency’s online application process, CDER Export Certification Application and Tracking System (CDEReCATS), under the following conditions:
These letters were part of FDA’s commitment under the Generic Drug User Fee Amendments of 2017 (GDUFA II), and as part of GDUFA III.